Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

NCT07040072 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

HNSCC

Interventions

COMBINATION_PRODUCT: Stapokibart and Finotonlimab

Sponsor

Beijing Tongren Hospital

Collaborators

[object Object]
[object Object]